Forget SPCX: As Continuous Volatility Shakes Tech, This $34 Exchange-Traded Fund Is a No-Brainer Buy Without The Post-IPO Risk

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • ARKX at $34 delivers diversified space exposure across launchers, satellite operators, and suppliers without underwriting a trillion-dollar valuation with zero public financials.

  • SPCX plunged from $220 to $185 in one week while ARKX holding RKLB posted 64% revenue growth and a $2.2B backlog.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Rocket Lab didn't make the cut. Grab the names FREE today.

Forget SPCX: As Continuous Volatility Shakes Tech, This $34 Exchange-Traded Fund Is a No-Brainer Buy Without The Post-IPO Risk

© bigjom jom / Shutterstock.com

SpaceX (NASDAQ:SPCX) is the only ticker financial media wants to discuss this week after its blockbuster public debut at an implied trillion-dollar valuation. But here’s what you should actually be watching.

The ARK Space Exploration & Innovation ETF (NYSEARCA:ARKX) trading near $34 a share offers diversified exposure to the space economy. Rocket launches and massive satellite arrays require billions in unceasing capital expenditure, and a single-name bet on a freshly listed giant is the worst way to underwrite that bill.

The SPCX Hype Cycle Is Already Cracking

SPCX went public on June 12, 2026 and the wheels have started to wobble inside a week. Shares opened to euphoria, briefly cleared $220 in overnight trading, and settled at $185 by June 18. Reddit sentiment collapsed from a bullish score of 76 on June 13 to a very bearish 12 by June 18, with the dominant retail post warning “SPCX, Beware, institutional money is NOT buying this trash on the open market” drawing over 1,000 upvotes in a single day. A separate top thread, “The math isn’t mathing on the SpaceX IPO,” drew over 1,000 comments.

That is textbook hype-cycle anatomy. Insider lockup expirations are still ahead. There is no public earnings history to underwrite. The implied market capitalization already prices in roughly a decade of flawless execution on Starlink, Starship, and Mars before SPCX has filed a single quarterly report as a public entity.

Why ARKX Offers Diversified Aerospace Exposure

1. You own the entire aerospace value chain. ARKX spreads capital intensity across launchers, satellite operators, propulsion suppliers, and ground-segment vendors. One Starship anomaly or one FAA delay does not blow up the position the way it would with a single ticker carrying a trillion-dollar valuation.

2. You capture public players printing real numbers. Consider Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction), the pure-play space stock that institutional aerospace funds anchor around. Rocket Lab posted Q1 2026 revenue of $200.35 million, up 63.5% year over year, with a $2.20 billion backlog and Q2 guidance of $225 million to $240 million. It joins the Nasdaq-100 Index on June 22, 2026 and was selected for the Department of War’s Space Based Interceptor program under Golden Dome for America. Audited, contracted revenue with a Pentagon stamp on it.

3. No lockup cliff, no dilution roulette. Fresh listings carry insider lockup expirations, secondary offerings, and price discovery that has wrecked plenty of trillion-dollar narratives in the first twelve months. A diversified basket sidesteps that mechanical headwind. You also get exposure to the whole sector for a fraction of one SPCX share, which matters when SPCX trades at $185 after a 14.94% one-week move.

The Risks, Stated Plainly

The space sector is volatile. Rocket Lab is down 15.76% over the past month, continues to post GAAP losses (a $45.02 million net loss in Q1), and is funding Neutron through ATM equity dilution. A diversified ETF softens those single-name shocks. It does not eliminate them.

The math is uncomplicated. SPCX wants you to underwrite a trillion-dollar valuation with zero public financials, days into a listing whose retail sentiment has already cratered. ARKX hands you the same launch-and-satellite tailwind through a basket stacked with operators like Rocket Lab, a company compounding revenue at 63.5% year over year and backlog at 20.2% sequentially.

The headline trade is crowded. The basket offers diversified exposure.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

TECH Vol: 51,552,079
MU Vol: 81,314,250
AMAT Vol: 16,000,867
GLW Vol: 25,152,246
TER Vol: 6,668,899

Top Losing Stocks

CTRA Vol: 73,319,495
AAPL Vol: 106,704,434
TJX Vol: 8,323,668
ROST Vol: 4,327,935
DELL Vol: 11,085,000